Researchers shared long-term follow-up data from the Colchicine-PCI trial, which compared colchicine administration before PCI with a placebo.

U.S. News & World Report's annual rankings of heart hospitals named Cleveland Clinic No. 1, once again, but there were many changes among the other top 25 hospitals. 

The first patient was enrolled in a multicenter clinical trial for the TaurusTrio transcatheter aortic valve replacement system, used for aortic regurgitation.

The FDA has categorized this as a Class I recall, which means using the devices “may cause serious injuries or death.”

The CardioVascular Coalition and Society for Cardiovascular Angiography and Interventions have both issued new statements highlighting their issues with the 2024 MPFS proposed rule. 

Teams from the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine will collaborate on the research. 

Making cardiac catheterization labs more efficient and less wasteful could help reduce the large carbon footprint associated with healthcare, according to a new commentary published in JACC: Cardiovascular Interventions.

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.